![Judy P. Ways](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Judy P. Ways
Plus aucun poste en cours
Finance
Health Technology
Profil
Judy P.
Ways formerly worked at Aventis Behring LLC, as Senior Director-Quality & Regulatory Compliance, MedImmune Ventures, Inc., as Vice President-Regulatory Affairs, Neuronetics, Inc., as VP-Regulatory Affairs & Quality Assurance, and Neuron Therapeutics, Inc., as VP-Regulatory Affairs & Quality Assurance.
Anciens postes connus de Judy P. Ways
| Sociétés | Poste | Fin |
|---|---|---|
Neuron Therapeutics, Inc. | Conseiller Juridique Général | - |
MedImmune Ventures, Inc.
 MedImmune Ventures, Inc. Investment ManagersFinance MedImmune Ventures invests in private biotechnology companies located across the globe primarily in North America. The firm focuses on healthcare sectors such as molecules, vaccines, pharmaceutical technologies, medical devices, diagnostics, imaging and healthcare IT. The firm provides financing for seed, early, later and mezzanine stage capital requirements with an investment size ranging from USD 5 - USD 10 million per round. It acts as a lead investor and takes an active role on the board of directors. | Public Communications Contact | 09/09/2009 |
Aventis Behring LLC | Conseiller Juridique Général | - |
| NEURONETICS, INC. | Conseiller Juridique Général | - |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Entreprise privées | 4 |
|---|---|
MedImmune Ventures, Inc.
MedImmune Ventures, Inc. Investment ManagersFinance MedImmune Ventures invests in private biotechnology companies located across the globe primarily in North America. The firm focuses on healthcare sectors such as molecules, vaccines, pharmaceutical technologies, medical devices, diagnostics, imaging and healthcare IT. The firm provides financing for seed, early, later and mezzanine stage capital requirements with an investment size ranging from USD 5 - USD 10 million per round. It acts as a lead investor and takes an active role on the board of directors. | Finance |
Neuronetics, Inc.
 Neuronetics, Inc. Medical SpecialtiesHealth Technology Develops and commercializes non-invasive therapies for psychiatric and neurological disorders | Health Technology |
Aventis Behring LLC | |
Neuron Therapeutics, Inc. |
